benzatropine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
atropine derivatives 333 86-13-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cogentin
  • benztropine mesilate
  • benzatropine
  • benztropine
  • tropine benzohydryl ether
  • benztropine mesylate
A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.
  • Molecular weight: 307.44
  • Formula: C21H25NO
  • CLOGP: 3.52
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 12.47
  • ALOGS: -5.41
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 mg O
2 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.21 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
BA (Bioavailability) 29 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1

Approvals:

DateAgencyCompanyOrphan
March 5, 1954 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 518.40 22.13 269 9383 144789 90474006
Tardive dyskinesia 222.28 22.13 71 9581 10859 90607936
Toxicity to various agents 218.70 22.13 206 9446 287640 90331155
Psychotic disorder 190.90 22.13 84 9568 31146 90587649
Granulocytopenia 152.47 22.13 47 9605 6394 90612401
Schizophrenia 148.83 22.13 57 9595 14857 90603938
Oculogyric crisis 141.28 22.13 36 9616 2443 90616352
Hallucination, auditory 120.85 22.13 50 9602 15925 90602870
Extrapyramidal disorder 103.31 22.13 45 9607 16258 90602537
Agitation 101.69 22.13 72 9580 67026 90551769
Paranoia 99.67 22.13 41 9611 12867 90605928
Akathisia 98.41 22.13 39 9613 11120 90607675
Cardiac arrest 88.89 22.13 80 9572 104855 90513940
Myocarditis 87.12 22.13 38 9614 13768 90605027
Neuroleptic malignant syndrome 87.04 22.13 39 9613 15057 90603738
Dyskinesia 86.83 22.13 52 9600 36482 90582313
Sedation 78.36 22.13 54 9598 48117 90570678
Drooling 78.09 22.13 26 9626 4520 90614275
Drug interaction 74.27 22.13 117 9535 276336 90342459
Muscle rigidity 73.15 22.13 34 9618 14275 90604520
Suicidal ideation 71.96 22.13 61 9591 73794 90545001
Tremor 68.58 22.13 83 9569 153090 90465705
Salivary hypersecretion 63.86 22.13 27 9625 9065 90609730
Catatonia 59.87 22.13 23 9629 6033 90612762
Treatment noncompliance 57.22 22.13 46 9606 51681 90567114
Encephalitis autoimmune 57.20 22.13 17 9635 2041 90616754
Dystonia 56.38 22.13 30 9622 16789 90602006
Delusion 55.95 22.13 28 9624 13812 90604983
Toxic encephalopathy 55.06 22.13 24 9628 8675 90610120
Haemoglobin urine 54.82 22.13 10 9642 134 90618661
Clonus 53.87 22.13 21 9631 5729 90613066
Eosinophil count abnormal 51.43 22.13 13 9639 853 90617942
Hyperreflexia 50.89 22.13 21 9631 6636 90612159
Ileus paralytic 49.16 22.13 19 9633 5066 90613729
Abnormal behaviour 48.10 22.13 30 9622 22598 90596197
Electrocardiogram QT prolonged 47.54 22.13 48 9604 72408 90546387
Aggression 45.98 22.13 31 9621 26637 90592158
Death 45.83 22.13 129 9523 456422 90162373
Schizoaffective disorder 45.41 22.13 18 9634 5129 90613666
Postmortem blood drug level 43.60 22.13 8 9644 111 90618684
Psychotic symptom 43.16 22.13 14 9638 2242 90616553
Tachycardia 42.64 22.13 67 9585 157606 90461189
Joint swelling 42.09 22.13 3 9649 503297 90115498
Hyperthermia 42.04 22.13 21 9631 10314 90608481
Red blood cells urine 41.61 22.13 10 9642 532 90618263
Parkinsonism 41.34 22.13 23 9629 14042 90604753
Suspected suicide 40.58 22.13 20 9632 9548 90609247
Mydriasis 39.95 22.13 23 9629 14989 90603806
Cardio-respiratory arrest 38.11 22.13 40 9612 63100 90555695
Mental status changes 37.66 22.13 34 9618 44645 90574150
Amaurosis 37.38 22.13 10 9642 820 90617975
Somnolence 37.28 22.13 74 9578 209010 90409785
Mental impairment 35.11 22.13 22 9630 16698 90602097
Croup infectious 34.39 22.13 9 9643 678 90618117
Impulsive behaviour 34.17 22.13 11 9641 1719 90617076
Restlessness 33.74 22.13 29 9623 35691 90583104
Schizoaffective disorder bipolar type 33.69 22.13 7 9645 190 90618605
Blood prolactin increased 33.07 22.13 13 9639 3624 90615171
Sinus tachycardia 32.90 22.13 26 9626 28487 90590308
Antidepressant drug level above therapeutic 32.32 22.13 8 9644 482 90618313
Torsade de pointes 31.94 22.13 20 9632 15162 90603633
Mania 30.71 22.13 19 9633 14105 90604690
Arthralgia 30.61 22.13 23 9629 778499 89840296
Pneumonia aspiration 30.34 22.13 29 9623 40911 90577884
Facial paralysis 29.05 22.13 19 9633 15515 90603280
Psychiatric decompensation 28.99 22.13 10 9642 1933 90616862
Hallucination 28.27 22.13 35 9617 65924 90552871
Unresponsive to stimuli 28.24 22.13 27 9625 38094 90580701
Abdominal discomfort 28.14 22.13 8 9644 477320 90141475
Hyperprolactinaemia 28.04 22.13 13 9639 5420 90613375
Pain 27.32 22.13 40 9612 996301 89622494
Swelling 26.67 22.13 6 9646 419052 90199743
Product dose omission issue 25.92 22.13 79 9573 291608 90327187
White blood cells urine positive 25.83 22.13 13 9639 6485 90612310
Cognitive disorder 25.31 22.13 34 9618 69373 90549422
Grandiosity 25.27 22.13 6 9646 303 90618492
Dysarthria 25.12 22.13 30 9622 54452 90564343
Food interaction 24.82 22.13 8 9644 1256 90617539
Mental disorder 24.15 22.13 23 9629 32295 90586500
Labelled drug-drug interaction issue 23.85 22.13 9 9643 2249 90616546
Respiratory arrest 23.56 22.13 23 9629 33288 90585507
Alopecia 23.05 22.13 12 9640 495059 90123736
Areflexia 22.86 22.13 10 9642 3643 90615152
Flat affect 22.44 22.13 8 9644 1703 90617092

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 279.22 20.18 224 11667 96241 42513203
Myocarditis 202.67 20.18 101 11790 18837 42590607
Granulocytopenia 195.98 20.18 74 11817 7040 42602404
Tardive dyskinesia 179.84 20.18 69 11822 6855 42602589
Toxicity to various agents 150.84 20.18 246 11645 228890 42380554
Extrapyramidal disorder 136.70 20.18 74 11817 16338 42593106
Neuroleptic malignant syndrome 136.17 20.18 81 11810 21391 42588053
Schizophrenia 123.97 20.18 60 11831 10490 42598954
Treatment noncompliance 122.75 20.18 94 11797 37578 42571866
Psychotic disorder 115.70 20.18 82 11809 29126 42580318
Sedation 112.57 20.18 82 11809 30393 42579051
Drug interaction 111.75 20.18 236 11655 266763 42342681
Cogwheel rigidity 105.64 20.18 33 11858 1768 42607676
Dystonia 104.63 20.18 57 11834 12733 42596711
Tremor 96.91 20.18 127 11764 96802 42512642
Hallucination, auditory 88.85 20.18 54 11837 14810 42594634
Anticholinergic syndrome 80.33 20.18 26 11865 1563 42607881
Head titubation 75.73 20.18 19 11872 450 42608994
Dystonic tremor 75.36 20.18 18 11873 345 42609099
Drooling 74.33 20.18 32 11859 4267 42605177
Agitation 73.30 20.18 90 11801 64224 42545220
Akathisia 70.36 20.18 41 11850 10410 42599034
Drug level below therapeutic 70.24 20.18 35 11856 6510 42602934
Drug abuse 62.64 20.18 108 11783 104663 42504781
Hyperprolactinaemia 61.78 20.18 23 11868 2100 42607344
Restlessness 56.29 20.18 54 11837 29195 42580249
Parkinsonism 51.96 20.18 34 11857 10589 42598855
Sinus tachycardia 51.27 20.18 44 11847 20609 42588835
Galactorrhoea 50.53 20.18 14 11877 491 42608953
Muscle rigidity 50.38 20.18 35 11856 12024 42597420
Abnormal behaviour 49.33 20.18 48 11843 26403 42583041
Priapism 48.12 20.18 27 11864 6380 42603064
Blood creatine phosphokinase increased 46.17 20.18 62 11829 48276 42561168
Gastrointestinal hypomotility 45.05 20.18 16 11875 1277 42608167
Delusion 44.11 20.18 35 11856 14699 42594745
Delirium 43.64 20.18 63 11828 52456 42556988
Aggression 42.71 20.18 57 11834 44106 42565338
Dysphemia 42.48 20.18 17 11874 1885 42607559
Product dose omission issue 41.24 20.18 115 11776 154250 42455194
Device leakage 40.98 20.18 29 11862 10256 42599188
Catatonia 40.73 20.18 24 11867 6215 42603229
Syringe issue 38.50 20.18 26 11865 8530 42600914
Dyskinesia 38.12 20.18 41 11850 25349 42584095
Thinking abnormal 37.68 20.18 24 11867 7137 42602307
Pericarditis 36.16 20.18 30 11861 13414 42596030
Mental status changes 35.68 20.18 51 11840 42064 42567380
Needle issue 35.68 20.18 25 11866 8702 42600742
Sedation complication 35.48 20.18 17 11874 2902 42606542
Febrile neutropenia 35.21 20.18 5 11886 185698 42423746
Schizoaffective disorder 35.16 20.18 15 11876 1955 42607489
Salivary hypersecretion 34.93 20.18 27 11864 10916 42598528
Mental disorder 34.14 20.18 33 11858 17996 42591448
Oculogyric crisis 33.37 20.18 14 11877 1751 42607693
Antipsychotic drug level increased 33.25 20.18 19 11872 4647 42604797
Somnolence 32.75 20.18 100 11791 141005 42468439
Muscle contracture 32.65 20.18 13 11878 1422 42608022
Serotonin syndrome 32.41 20.18 38 11853 25807 42583637
Eosinophilic pleural effusion 32.10 20.18 9 11882 330 42609114
Drug level increased 31.99 20.18 38 11853 26162 42583282
Confusional state 31.90 20.18 111 11780 167486 42441958
Dissociation 31.25 20.18 17 11874 3781 42605663
Suicidal ideation 30.52 20.18 51 11840 48110 42561334
Lethargy 30.18 20.18 50 11841 46840 42562604
Faecalith 29.81 20.18 5 11886 12 42609432
Disease progression 29.36 20.18 3 11888 143653 42465791
Rhabdomyolysis 29.06 20.18 66 11825 77953 42531491
Troponin increased 29.00 20.18 31 11860 19031 42590413
Cerebral amyloid angiopathy 28.95 20.18 8 11883 278 42609166
Blood prolactin increased 26.77 20.18 13 11878 2285 42607159
Blood pH decreased 26.77 20.18 13 11878 2285 42607159
Non-high-density lipoprotein cholesterol increased 26.68 20.18 7 11884 199 42609245
Drug level decreased 26.28 20.18 22 11869 9955 42599489
Diarrhoea 26.25 20.18 56 11835 460793 42148651
Anaemia 25.97 20.18 24 11867 280254 42329190
Faecaloma 25.72 20.18 18 11873 6252 42603192
Left ventricular dysfunction 25.53 20.18 23 11868 11478 42597966
Rash 25.33 20.18 24 11867 276930 42332514
Parasomnia 25.04 20.18 8 11883 461 42608983
Antipsychotic drug level decreased 24.36 20.18 10 11881 1183 42608261
Tri-iodothyronine decreased 24.25 20.18 6 11885 134 42609310
Hallucination 24.08 20.18 51 11840 57456 42551988
Unmasking of previously unidentified disease 24.08 20.18 10 11881 1219 42608225
Tachycardia 23.77 20.18 72 11819 101015 42508429
Echocardiogram abnormal 23.76 20.18 10 11881 1260 42608184
Arthralgia 23.62 20.18 14 11877 205224 42404220
Paranoia 23.46 20.18 24 11867 14002 42595442
Pneumonia 23.45 20.18 52 11839 422097 42187347
Mania 23.23 20.18 21 11870 10526 42598918
Intentional overdose 23.14 20.18 47 11844 51409 42558035
Product administered at inappropriate site 23.11 20.18 13 11878 3085 42606359
Dysarthria 22.40 20.18 40 11851 39767 42569677
Gynaecomastia 21.92 20.18 22 11869 12545 42596899
Globulins increased 21.51 20.18 7 11884 428 42609016
Thyroxine decreased 21.45 20.18 6 11885 218 42609226
White blood cell count increased 21.25 20.18 42 11849 45045 42564399
Device malfunction 20.45 20.18 21 11870 12306 42597138
Memory impairment 20.40 20.18 44 11847 50178 42559266
Antipsychotic drug level above therapeutic 20.38 20.18 9 11882 1275 42608169
Autonomic nervous system imbalance 20.37 20.18 12 11879 3104 42606340
Pain 20.36 20.18 23 11868 244825 42364619
Bipolar disorder 20.27 20.18 13 11878 3909 42605535

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Completed suicide 825.17 20.28 506 17702 241875 110329216
Tardive dyskinesia 372.58 20.28 123 18085 13456 110557635
Granulocytopenia 364.27 20.28 119 18089 12596 110558495
Toxicity to various agents 361.76 20.28 419 17789 480136 110090955
Myocarditis 274.33 20.28 122 18086 29933 110541158
Psychotic disorder 224.18 20.28 126 18082 50811 110520280
Neuroleptic malignant syndrome 211.45 20.28 106 18102 33953 110537138
Schizophrenia 210.13 20.28 92 18116 21734 110549357
Drug interaction 187.40 20.28 312 17896 499871 110071220
Agitation 173.78 20.28 146 18062 112905 110458186
Extrapyramidal disorder 165.06 20.28 85 18123 28782 110542309
Hallucination, auditory 154.61 20.28 79 18129 26318 110544773
Oculogyric crisis 151.99 20.28 46 18162 3786 110567305
Tremor 149.23 20.28 175 18033 202057 110369034
Treatment noncompliance 145.84 20.28 110 18098 72880 110498211
Dystonia 144.70 20.28 75 18133 25730 110545361
Sedation 139.18 20.28 105 18103 69578 110501513
Drooling 105.85 20.28 41 18167 7098 110563993
Akathisia 105.41 20.28 53 18155 17060 110554031
Muscle rigidity 104.47 20.28 59 18149 23972 110547119
Catatonia 97.10 20.28 44 18164 11256 110559835
Salivary hypersecretion 95.85 20.28 50 18158 17371 110553720
Dystonic tremor 89.83 20.28 19 18189 358 110570733
Delusion 89.12 20.28 53 18155 23702 110547389
Dyskinesia 88.53 20.28 71 18137 51375 110519716
Drug abuse 84.73 20.28 124 18084 177287 110393804
Cogwheel rigidity 83.67 20.28 29 18179 3669 110567422
Parkinsonism 81.93 20.28 49 18159 22138 110548953
Aggression 81.82 20.28 72 18136 59138 110511953
Paranoia 81.55 20.28 49 18159 22325 110548766
Restlessness 80.94 20.28 70 18138 56189 110514902
Suicidal ideation 75.44 20.28 85 18123 93852 110477239
Death 72.60 20.28 266 17942 698603 109872488
Schizoaffective disorder 72.53 20.28 25 18183 3111 110567980
Mental status changes 71.82 20.28 75 18133 76047 110495044
Product dose omission issue 71.25 20.28 161 18047 321621 110249470
Hyperprolactinaemia 70.76 20.28 30 18178 6545 110564546
Abnormal behaviour 69.56 20.28 55 18153 38984 110532107
Sinus tachycardia 67.34 20.28 57 18151 44436 110526655
Arthralgia 64.42 20.28 24 18184 779608 109791483
Device leakage 63.33 20.28 37 18171 16011 110555080
Syringe issue 63.10 20.28 31 18177 9494 110561597
Blood creatine phosphokinase increased 60.16 20.28 67 18141 73010 110498081
Tachycardia 60.04 20.28 122 18086 226523 110344568
Needle issue 59.71 20.28 37 18171 17803 110553288
Galactorrhoea 58.55 20.28 23 18185 4132 110566959
Cardio-respiratory arrest 58.25 20.28 83 18125 115753 110455338
Hallucination 57.49 20.28 77 18131 101355 110469736
Priapism 57.34 20.28 25 18183 5836 110565255
Cardiac arrest 55.81 20.28 109 18099 196644 110374447
Anticholinergic syndrome 54.42 20.28 22 18186 4258 110566833
Joint swelling 52.05 20.28 6 18202 442839 110128252
Ileus paralytic 51.50 20.28 29 18179 11708 110559383
Pain 50.26 20.28 50 18158 954905 109616186
Antipsychotic drug level increased 49.98 20.28 24 18184 6991 110564100
Mania 49.81 20.28 35 18173 20761 110550330
Haemoglobin urine 49.48 20.28 10 18198 149 110570942
Hyperreflexia 48.70 20.28 26 18182 9459 110561632
Intentional overdose 48.49 20.28 82 18126 132419 110438672
Encephalitis autoimmune 47.86 20.28 19 18189 3509 110567582
Delirium 47.36 20.28 82 18126 134943 110436148
Somnolence 47.05 20.28 131 18077 297318 110273773
Suspected suicide 47.04 20.28 30 18178 15169 110555922
Gastrointestinal hypomotility 46.62 20.28 17 18191 2491 110568600
Dysarthria 44.84 20.28 62 18146 84059 110487032
Rhabdomyolysis 44.70 20.28 75 18133 120326 110450765
Drug level below therapeutic 43.66 20.28 26 18182 11647 110559444
Mental disorder 43.53 20.28 42 18166 38749 110532342
Diarrhoea 43.28 20.28 76 18132 1139429 109431662
Eosinophil count abnormal 43.05 20.28 13 18195 1061 110570030
Respiratory arrest 40.52 20.28 49 18159 58250 110512841
Antipsychotic drug level above therapeutic 39.71 20.28 15 18193 2425 110568666
Blood prolactin increased 39.64 20.28 18 18190 4624 110566467
Clonus 39.50 20.28 22 18186 8694 110562397
Psychotic symptom 39.48 20.28 17 18191 3850 110567241
Mental impairment 38.41 20.28 31 18177 22608 110548483
Drug level increased 37.98 20.28 43 18165 47676 110523415
Gynaecomastia 37.76 20.28 22 18186 9468 110561623
Eosinophilic pleural effusion 37.54 20.28 10 18198 518 110570573
Device malfunction 37.15 20.28 32 18176 25526 110545565
Troponin increased 36.78 20.28 34 18174 29732 110541359
Neutrophil count increased 36.05 20.28 36 18172 34616 110536475
Head titubation 36.03 20.28 12 18196 1345 110569746
Alopecia 36.00 20.28 8 18200 364745 110206346
Faecaloma 35.49 20.28 25 18183 14883 110556208
Red blood cells urine 35.21 20.28 10 18198 658 110570433
Thinking abnormal 35.14 20.28 25 18183 15115 110555976
Mydriasis 34.79 20.28 29 18179 22128 110548963
Persecutory delusion 34.44 20.28 18 18190 6273 110564818
Muscle contracture 34.22 20.28 14 18194 2794 110568297
Confusional state 34.03 20.28 160 18048 468520 110102571
Unmasking of previously unidentified disease 33.93 20.28 14 18194 2854 110568237
White blood cell count increased 32.89 20.28 58 18150 96784 110474307
Toxic encephalopathy 32.75 20.28 24 18184 15190 110555901
Unresponsive to stimuli 32.48 20.28 46 18162 63744 110507347
Dissociation 31.89 20.28 20 18188 9822 110561269
Anaemia 31.88 20.28 26 18182 547060 110024031
Swelling 30.32 20.28 10 18198 351031 110220060
Psychiatric decompensation 30.15 20.28 16 18192 5749 110565342
Inappropriate schedule of product administration 29.56 20.28 87 18121 203550 110367541
Hypersensitivity 29.25 20.28 15 18193 403983 110167108
Electroconvulsive therapy 29.23 20.28 6 18202 97 110570994
Lethargy 29.17 20.28 54 18154 93522 110477569
General physical health deterioration 29.04 20.28 17 18191 425278 110145813
Faecalith 28.98 20.28 5 18203 29 110571062
Wheezing 28.66 20.28 4 18204 255226 110315865
Neutrophilia 28.56 20.28 19 18189 10310 110560781
Cerebral amyloid angiopathy 27.87 20.28 8 18200 547 110570544
Serotonin syndrome 27.70 20.28 41 18167 59112 110511979
Autonomic nervous system imbalance 27.32 20.28 15 18193 5765 110565326
Postmortem blood drug level 27.28 20.28 7 18201 313 110570778
Leukopenia 27.00 20.28 69 18139 148722 110422369
Disease progression 26.99 20.28 4 18204 244030 110327061
Blister 26.90 20.28 3 18205 227373 110343718
Electrocardiogram QT prolonged 26.88 20.28 57 18151 108903 110462188
Lower respiratory tract infection 26.85 20.28 4 18204 243102 110327989
Croup infectious 26.75 20.28 9 18199 1041 110570050
Overdose 26.73 20.28 92 18116 233702 110337389
Amaurosis 26.70 20.28 10 18198 1579 110569512
Stomatitis 26.51 20.28 6 18202 270236 110300855
Bipolar disorder 25.96 20.28 17 18191 8990 110562101
Drug hypersensitivity 25.93 20.28 22 18186 454068 110117023
Oedema peripheral 25.64 20.28 11 18197 328649 110242442
Non-high-density lipoprotein cholesterol increased 25.59 20.28 7 18201 401 110570690
Parasomnia 25.28 20.28 8 18200 763 110570328
Agranulocytosis 24.98 20.28 40 18168 61720 110509371
Sinusitis 24.67 20.28 9 18199 296679 110274412
Pruritus 24.63 20.28 36 18172 581524 109989567
Neutropenia 24.38 20.28 124 18084 374496 110196595
Dyspnoea 24.27 20.28 97 18111 1106775 109464316
Infection 23.99 20.28 15 18193 362185 110208906
Pain in extremity 23.89 20.28 27 18181 487091 110084000
Hyperthermia 23.80 20.28 23 18185 21249 110549842
Peripheral swelling 23.78 20.28 19 18189 404015 110167076
Pneumonia aspiration 23.00 20.28 45 18163 81188 110489903
Fatigue 22.78 20.28 113 18095 1215845 109355246
Product administered at inappropriate site 22.78 20.28 13 18195 5380 110565711
Febrile neutropenia 22.57 20.28 12 18196 316755 110254336
Abdominal pain 22.47 20.28 31 18177 512958 110058133
Maternal exposure during pregnancy 22.46 20.28 7 18201 254876 110316215
Antipsychotic drug level below therapeutic 22.34 20.28 9 18199 1726 110569365
Headache 22.19 20.28 73 18135 882304 109688787
Muscle twitching 22.18 20.28 26 18182 29909 110541182
Tic 22.04 20.28 11 18197 3482 110567609
Brain injury 21.91 20.28 18 18190 13458 110557633
Mobility decreased 21.88 20.28 6 18202 237416 110333675
Blood pH decreased 21.75 20.28 12 18196 4657 110566434
Homicidal ideation 21.65 20.28 11 18197 3616 110567475
Contraindicated product administered 21.56 20.28 7 18201 248260 110322831
Clang associations 21.55 20.28 4 18204 37 110571054
Abdominal discomfort 21.38 20.28 20 18188 393838 110177253
Antidepressant drug level above therapeutic 21.32 20.28 7 18201 750 110570341
Withdrawal syndrome 21.19 20.28 26 18182 31354 110539737
White blood cells urine positive 21.19 20.28 14 18194 7510 110563581
Constipation 20.93 20.28 115 18093 357671 110213420
Suicide attempt 20.93 20.28 50 18158 103344 110467747
Somnambulism 20.71 20.28 13 18195 6392 110564699
Discomfort 20.60 20.28 5 18203 214702 110356389
Refusal of treatment by patient 20.49 20.28 15 18193 9479 110561612
Paraesthesia 20.41 20.28 10 18198 276511 110294580

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N04AC01 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
ANTICHOLINERGIC AGENTS
Ethers of tropine or tropine derivatives
FDA MoA N0000000207 Histamine Receptor Antagonists
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic
CHEBI has role CHEBI:48407 antiparkinson drug
CHEBI has role CHEBI:48876 muscarinic antagonist
CHEBI has role CHEBI:50370 parasympatholytic
CHEBI has role CHEBI:66956 antidyskinesia agent
CHEBI has role CHEBI:146270 oneirogen
MeSH PA D000978 Antiparkinson Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018765 Dopamine Uptake Inhibitors
MeSH PA D049990 Membrane Transport Modulators
FDA EPC N0000175750 Antihistamine
CHEBI has role CHEBI:35480 analgesic

Related Drugs by ATC class:

N04AC Ethers of tropine or tropine derivatives 1 drug
etybenzatropine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Postencephalitic parkinsonism indication 19972008 DOID:14332
Parkinsonism indication 32798002
Parkinson's disease indication 49049000 DOID:14330
Extrapyramidal disease indication 76349003
Arteriosclerotic Parkinsonism indication
Urinary tract obstruction contraindication 7163005 DOID:5200
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Severe chronic ulcerative colitis contraindication 14311001
Disorder of autonomic nervous system contraindication 15241006
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Shigellosis contraindication 36188001
Hypertensive disorder contraindication 38341003 DOID:10763
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Dysuria contraindication 49650001
Paralytic ileus contraindication 55525008 DOID:8442
Ulcerative colitis contraindication 64766004 DOID:8577
Hiatal hernia contraindication 84089009 DOID:12642
Open-angle glaucoma contraindication 84494001 DOID:1067
Kidney disease contraindication 90708001 DOID:557
Thyrotoxicosis contraindication 90739004 DOID:7997
Myasthenia gravis contraindication 91637004 DOID:437
Tardive dyskinesia contraindication 102449007
Dysentery contraindication 111939009
Gastrointestinal obstruction contraindication 126765001
Bleeding contraindication 131148009
Gastroesophageal reflux disease contraindication 235595009 DOID:8534
Disease of liver contraindication 235856003 DOID:409
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Fever contraindication 386661006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Pseudomembranous enterocolitis contraindication 397683000
Gastric ulcer contraindication 397825006 DOID:10808
Disorder of coronary artery contraindication 414024009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.86 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9.64 WOMBAT-PK CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.23 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter IC50 4.62 CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.86 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 8.16 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.90 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.50 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.89 DRUG MATRIX
Alpha-2B adrenergic receptor GPCR Ki 7.52 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.65 DRUG MATRIX
Histamine H1 receptor GPCR Ki 8.96 WOMBAT-PK
Histamine H2 receptor GPCR Ki 5.93 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 8.85 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 8.96 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR ANTAGONIST Ki 8.96 WOMBAT-PK
Muscarinic acetylcholine receptor M5 GPCR ANTAGONIST Ki 8.55 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.24 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Kd 7.25 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.59 DRUG MATRIX
Alpha-2A adrenergic receptor GPCR Ki 6.69 DRUG MATRIX
Sodium-dependent neutral amino acid transporter B(0)AT1 Transporter INHIBITOR IC50 4.36 IUPHAR
Alpha-1B adrenergic receptor GPCR Ki 7.39 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.95 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 6.85 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 8.59 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 9.23 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.29 CHEMBL
Sodium-dependent dopamine transporter Transporter Ki 6.93 CHEMBL

External reference:

IDSource
D00778 KEGG_DRUG
132-17-2 SECONDARY_CAS_RN
1424 RXNORM
C0005098 UMLSCUI
CHEBI:3048 CHEBI
CXQ PDB_CHEM_ID
CHEMBL1201203 ChEMBL_ID
CHEMBL1200383 ChEMBL_ID
DB00245 DRUGBANK_ID
7601 IUPHAR_LIGAND_ID
1201549 PUBCHEM_CID
3130 MMSL
4264 MMSL
563 MMSL
d00175 MMSL
D001590 MESH_DESCRIPTOR_UI
292 INN_ID
4017824 VANDF
4019630 VANDF
1NHL2J4X8K UNII
001647 NDDF
004667 NDDF
29527005 SNOMEDCT_US
372846002 SNOMEDCT_US
77390008 SNOMEDCT_US
1NHL2J4X8K INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9233 INJECTION 1 mg INTRAMUSCULAR ANDA 15 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9729 INJECTION 1 mg INTRAMUSCULAR ANDA 14 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2433 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2434 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0603-2435 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8222 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8223 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0615-8478 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7288 TABLET 0.50 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7289 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7290 TABLET 2 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 10135-606 TABLET 0.50 mg ORAL ANDA 15 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 10135-607 TABLET 1 mg ORAL ANDA 15 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 10135-608 TABLET 2 mg ORAL ANDA 15 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 10135-813 TABLET 0.50 mg ORAL ANDA 14 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 10135-814 TABLET 1 mg ORAL ANDA 14 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 10135-815 TABLET 2 mg ORAL ANDA 14 sections
benztropine mesylate HUMAN PRESCRIPTION DRUG LABEL 1 10858-011 INJECTION 1 mg INTRAMUSCULAR ANDA 1 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 11534-167 TABLET 0.50 mg ORAL ANDA 12 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 11534-168 TABLET 1 mg ORAL ANDA 12 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 11534-169 TABLET 2 mg ORAL ANDA 12 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 21695-286 TABLET 2 mg ORAL ANDA 15 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 43353-796 TABLET 1 mg ORAL ANDA 16 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 43353-913 TABLET 0.50 mg ORAL ANDA 16 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 50090-3882 TABLET 2 mg ORAL ANDA 13 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 50090-3883 TABLET 2 mg ORAL ANDA 13 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4082 TABLET 1 mg ORAL ANDA 15 sections
BENZTROPINE MESYLATE HUMAN PRESCRIPTION DRUG LABEL 1 50090-6022 TABLET 1 mg ORAL ANDA 13 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 50090-7017 TABLET 1 mg ORAL ANDA 14 sections
Benztropine Mesylate HUMAN PRESCRIPTION DRUG LABEL 1 50228-225 TABLET 0.50 mg ORAL ANDA 14 sections